India’s ATLAS expands to OTCs
This article was originally published in The Tan Sheet
Executive SummaryATLAS Laboratories and Pharmaceuticals, an Indian manufacturer of Rx hormonal preparations and anti-hypertensive products, plans to enter the over-the-counter segment with a line of women's health products, the company announces Oct. 16. ATLAS Executive Director Ashwin Kapur says the New Delhi-based firm "will leverage our vertical presence in the ethical segment, to develop a strong network for OTC products" for women, whom he calls "the backbone of our society." Kapur adds the Indian OTC channel's average compound annual growth rate of 14 percent attracted the firm to the market. The company says it intends to add a large R&D facility and look for international partnerships to launch new molecules in the Indian market
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.